31R Stock Overview A life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Revive Therapeutics Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Revive Therapeutics Historical stock prices Current Share Price CA$0.0005 52 Week High CA$0.029 52 Week Low CA$0.0005 Beta 0.21 1 Month Change 0% 3 Month Change -90.00% 1 Year Change -96.43% 3 Year Change -99.80% 5 Year Change -98.00% Change since IPO -99.67%
Recent News & Updates
Revive Therapeutics Ltd. Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure Nov 01
Revive Therapeutics Ltd. Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures Sep 18
Revive Therapeutics Ltd. Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure Jul 03
Revive Therapeutics Ltd. Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long Covid Jun 14
Revive Therapeutics Ltd. Provides Update from FDA Meeting for Long Covid Diagnostic Product Jun 13
New major risk - Financial position Jun 04 See more updates
Revive Therapeutics Ltd. Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure Nov 01
Revive Therapeutics Ltd. Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures Sep 18
Revive Therapeutics Ltd. Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure Jul 03
Revive Therapeutics Ltd. Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long Covid Jun 14
Revive Therapeutics Ltd. Provides Update from FDA Meeting for Long Covid Diagnostic Product Jun 13
New major risk - Financial position Jun 04
Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product Apr 19
Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder Apr 02
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID Mar 28 Revive Therapeutics Ltd. announced that it has received CAD 2.10061 million in funding Feb 27
Revive Therapeutics Explores the Use of Bucillamine for Long COVID Feb 03
New minor risk - Shareholder dilution Feb 02 Revive Therapeutics Ltd. announced that it expects to receive CAD 3 million in funding Jan 25
Revive Therapeutics Ltd. Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada Jan 17
Revive Therapeutics Ltd. Successfully Completes Development of A Novel Lyophilized Formulation of Bucillamine Jan 10
Revive Therapeutics Ltd. Provides Update of Novel Bucillamine Formulation Development Nov 22
Revive Therapeutics Ltd. Provides Update of Novel Bucillamine Formulation Development Oct 12
Revive Therapeutics Ltd., Annual General Meeting, Dec 19, 2023 Oct 06
New major risk - Market cap size Oct 05
Revive Therapeutics Ltd. Announces Initiation of Novel Bucillamine Formulation Development Aug 23
New major risk - Market cap size Jul 07
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 Jul 07
Revive Therapeutics Ltd. Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 May 31
Revive Therapeutics Ltd. Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of Covid-19 Jan 20 Revive Therapeutics Ltd. To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 Revive Therapeutics Ltd. Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of Covid-19 Jan 06
Revive Therapeutics Ltd. announced that it expects to receive CAD 5 million in funding from EMD Financial Inc. Dec 02
Revive Therapeutics Ltd. announced that it expects to receive CAD 5 million in funding from EMD Financial Inc. Dec 01
Revive Therapeutics Ltd. Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 Nov 23
High number of new and inexperienced directors Nov 16
Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA Oct 15
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19 Sep 29
Revive Therapeutics Ltd. Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program Sep 17
Revive Therapeutics Ltd. Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA Sep 15
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19 Aug 17
Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Jul 26
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Jun 25
Revive Therapeutics Ltd., Annual General Meeting, Aug 03, 2022 Jun 09
Revive Therapeutics Ltd. Provides Update on U.S. Food & Drug Administration Phase 3 Clinical Trial for Bucillamine in COVID-19 Jun 07
Revive Therapeutics Ltd. Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation Jun 01
Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19 May 27
Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 May 17
High number of new and inexperienced directors Apr 27
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Apr 26
Revive Therapeutics Announces Publication of Research Data with Bucillamine in Covid-19 Apr 19
Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Apr 12
Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Mar 31
Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19 Feb 16
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Jan 19
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs Jan 18
Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19 Jan 07
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Dec 30
Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial Dec 05
Revive Therapeutics Ltd. to Provide an Update on its Psychedelics Development and Clinical Programs with a Focus on Psilocybin Aug 12
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Jul 16
Revive Therapeutics Ltd. Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application Mar 21
Revive Therapeutics Ltd. Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request Feb 27
Revive Therapeutics Ltd. Provides Update on Cannabinoid Pharmaceuticals Program Feb 12
Revive Therapeutics Ltd., Annual General Meeting, Apr 05, 2021 Feb 05
Revive Therapeutics Announces Research Collaboration with North Carolina State University Jan 15
Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study Jan 02
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access Dec 25
Revive Therapeutics Ltd. Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics Nov 19
Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin Nov 12
Revive Therapeutics Ltd. Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Oct 27
Revive Therapeutics Ltd. Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Sep 30
Revive Therapeutics Ltd. Announces Clinical Study of Psilocybin in the Treatment of Methamphetamine Use Disorder Sep 22
Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19 Sep 17 Shareholder Returns 31R DE Pharmaceuticals DE Market 7D -83.3% -0.3% -0.2% 1Y -96.4% -17.0% 7.0%
See full shareholder returns
Return vs Market: 31R underperformed the German Market which returned 7% over the past year.
Price Volatility Is 31R's price volatile compared to industry and market? 31R volatility 31R Average Weekly Movement 906.4% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 31R's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 31R's weekly volatility has decreased from 994% to 906% over the past year, but is still higher than 75% of German stocks.
About the Company Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases.
Show more Revive Therapeutics Ltd. Fundamentals Summary How do Revive Therapeutics's earnings and revenue compare to its market cap? 31R fundamental statistics Market cap €2.79m Earnings (TTM ) -€3.80m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 31R income statement (TTM ) Revenue CA$0 Cost of Revenue CA$0 Gross Profit CA$0 Other Expenses CA$5.70m Earnings -CA$5.70m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 12:34 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Revive Therapeutics Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Doug Cooper Beacon Securities Limited
Show 0 more analysts 
